

# Calcium Supplements Tied to Higher MI Risk

BY MITCHEL L. ZOLER

FROM THE ANNUAL MEETING OF  
THE AMERICAN SOCIETY FOR  
BONE AND MINERAL RESEARCH

TORONTO – Calcium supplements appear to cause more harm than good, according to a meta-analysis of 28,000 participants in nine trials that include a new analysis of more than 16,000 participants in the Women's Health Initiative, but the re-analysis has raised concerns among the WHI's original investigators.

"We calculate that for every 1,000 people treated with calcium for 5 years, it will lead to four additional myocardial infarctions, four additional strokes, and two additional deaths, while preventing three fractures," Dr. Ian R. Reid said at the meeting.

**VITALS** **Major Finding:** People taking a calcium supplement showed a statistically significant 24% excess relative risk for MI, a 15% excess relative risk for stroke, and a 16% excess relative risk for MI or stroke.

**Data Source:** Meta-analysis of nine studies that compared calcium supplements with placebo in a total of more than 28,000 people.

**Disclosures:** Dr. Reid said that he had no relevant disclosures.

"I don't prescribe calcium supplements to anyone anymore for preventing bone fractures. People should get calcium from their diet," said Dr. Reid, a professor of medicine at the University of Auckland, New Zealand.

"We believe there is a fundamental difference between dietary calcium and supplemental calcium." He speculated that a calcium supplement, even at a relatively modest dose of 500 mg, produces a "borderline hypercalcemia" that persists for several hours and raises the risk for myocardial infarction or stroke, the same way that people in the highest quartile for normal blood calcium levels have an increased risk for cardiovascular disease events.

But the researchers who ran the Women's Health Initiative (WHI) study questioned the legitimacy of the new analysis beyond a hypothesis-generating exercise.

"The WHI investigators have concerns about the reanalysis and whether omitting the subgroups with favorable results is appropriate," commented Dr. JoAnn E. Manson, professor of medicine at Harvard University and chief of the division of preventive medicine at Brigham and Women's Hospital, both in Boston, and a WHI coinvestigator.

Dr. Reid and his associates initially documented their finding that calcium supplements raise cardiovascular risk in a pair of meta-analyses published online last July (BMJ 2010;341:c3691). They reported that calcium supplement use was linked with a statistically significant 27% and 31% relatively increased risk

for myocardial infarction in two separate meta-analyses.

To further explore the impact of calcium supplements on cardiovascular risk, they received permission from the National Heart, Lung, and Blood Institute to reanalyze data collected in a WHI study of more than 36,000 postmenopausal women randomized to receive a daily supplement with 500 mg calcium plus vitamin D or placebo.

The original report from the WHI investigators showed that the calcium plus vitamin D treatment did not significantly increase or decrease coronary or cerebrovascular risk in generally healthy postmenopausal women during 7 years of treatment (Circulation 2007;115:846-54).

But the WHI study design allowed the participants to take more calcium supplements in addition to their study

agent, if they wanted to do so. At baseline, more than 19,000 (54%) of the women in the study reported using a calcium supplement on their own, and at the end of the study 69% reported the practice, Dr. Reid said. To address the possible confounding this may have caused, he focused his analysis on the 16,718 women in the WHI study who reported not using a personal calcium supplement at entry into the study.



## iPro™ Continuous Glucose Monitoring (CGM) can help you discover glycemic excursions not revealed by self-monitoring of blood glucose (SMBG) alone

- The American Diabetes Association recommends that patients with diabetes using multiple insulin injections perform SMBG three or more times daily<sup>1</sup>
- iPro CGM provides up to 12 glucose values per hour and up to 288 values per day,<sup>2</sup> a rate unrealistic for patients to achieve with SMBG alone

## Get the insights you need to make informed treatment decisions

- Continuous Glucose Monitoring aided identification of unrecognized hypoglycemia in patients with type 1 diabetes<sup>3</sup>
- Continuous Glucose Monitoring assisted in determining insulin therapy modifications<sup>3</sup>

## Indications for Use

- iPro CGM is intended to continuously record interstitial glucose levels in persons with diabetes mellitus
- This information is intended to supplement, not replace, blood glucose information obtained using standard home glucose monitoring devices

Please see Important Safety Information on adjacent page or request a copy of the iPro CGM user guides from your Medtronic sales representative.

For more information, please contact Medtronic at 1-888-350-3245.

**iPro™**  
Professional CGM

In this subgroup, the MI rate ran 2.5% in women randomized to calcium supplement treatment, and 2.0% among women in the placebo arm, a 22% relative increased MI rate with the calcium supplement that was statistically significant. The rate of MI or stroke ran a relative 16% higher among the women taking the calcium supplement, which was also statistically significant. The results showed no significant effect of calcium supplementation on stroke rate. "We saw the same effect as in the meta-analysis," Dr. Reid said.

But if Dr. Reid's analysis did not start

with a prior hypothesis, this finding can only be considered hypothesis generat-



**The evidence for an increased MI risk is stronger than the evidence that supplements prevent bone fractures.**

DR. REID

ing, not hypothesis testing, Dr. Manson said in an interview. "Many subgroups

were tested in the WHI, and some would be expected to show significant effect modification by chance," she pointed out. In addition, randomization made background levels of calcium use similar in the two treatment arms and thereby neutralized background calcium use as a possible confounder. Dr. Manson also noted that if supplemental calcium posed a risk, the event rates should have been highest among women taking both the study calcium dose and an additional dose on their own.

When the Auckland researchers added the results from the WHI subanalysis to

their previously reported meta-analysis, they "just reinforced the trends and made them more significant," Dr. Reid said in an interview.

When data from the WHI subgroup that did not use personal calcium supplements at baseline were added to the meta-analysis, the results showed that those who did take supplements had a 24% relative excess of MIs, a 15% relative excess of stroke, and a 16% relative excess of MI or stroke, he reported.



**There are concerns about 'whether omitting the subgroups with favorable results is appropriate.'**

DR. MANSON

## Indications for Use

The CGMS *iPro* Digital Recorder is intended to continuously record interstitial glucose levels in persons with diabetes mellitus. This information is intended to supplement, not replace, blood glucose information obtained using standard home glucose monitoring devices. The information collected by the digital recorder may be downloaded and displayed on a computer and reviewed by healthcare professionals.

This information may allow identification of patterns of glucose-level excursions above or below the desired range, facilitating therapy adjustments which may minimize these excursions.

The CGMS *iPro* Digital Recorder:

- Is intended for prescription use only.
- Will not allow readings to be made available directly to patients in real time.
- Provides readings that will be available for review by physicians after the recording interval (72 hours).
- Is currently intended for occasional rather than everyday use.
- Is to be used only as a supplement to, and not a replacement for, standard invasive measurement.
- Is not intended to change patient management based on the numbers generated, but to guide future management of the patient based on response to trends noticed. That is, these trends or patterns may be used to suggest when to take fingerstick glucose measurements to better manage the patient.

The glucose sensor, tester, charger, and CGMS *iProWand* are intended for use with the CGMS *iPro* Digital Recorder. The Sen-serter® device is indicated only for insertion of the Medtronic MiniMed glucose sensor.

## Important Safety Information

### Contraindication

Do not use magnetic mattress pads while wearing the CGMS *iPro* Digital Recorder.

### Warning

Product contains small parts and may pose a choking hazard for young children.

## Important Safety Information, continued

### Sensor

The glucose sensor should be removed if redness, bleeding, pain, tenderness, irritation, or inflammation develops at insertion site, or if you experience unexplained fever. An optional occlusive dressing should be removed if irritation or reaction to the tape develops.

The glucose sensor may create special needs regarding your patients' medical conditions or medications. Healthcare professionals should discuss this with their patients before they use the glucose sensor.

Wait 5 minutes after glucose sensor insertion before setting up the CGMS *iPro* Digital Recorder with Solutions CGMS *iPro*.

- Make sure that the site is not bleeding before connection.
- If bleeding occurs, apply steady pressure with a sterile gauze or clean cloth at the insertion site until bleeding stops. After bleeding stops, attach the digital recorder to the glucose sensor.
- If bleeding persists after 3 minutes, remove the glucose sensor and discard. Insert a new glucose sensor in a different location.

Contact the 24 Hour HelpLine if you experience any adverse reactions associated with the digital recorder or glucose sensor.

### Precautions

If performing multiple CGMS *iPro* Digital Recorder studies on the same patient, establish a rotation schedule for choosing new glucose sensor sites. Avoid sites that are constrained by clothing, have scar tissue, or are subject to rigorous movement during exercise.

**For additional information, please consult the *iPro* CGM user guides.**

*iPro*™ is a trademark of Medtronic MiniMed, Inc.  
Sen-serter® is a registered trademark of Medtronic MiniMed, Inc.

### References

1. American Diabetes Association. *Diabetes Care*. 2010; 33(suppl 1):S11-S61.
2. Solutions® Software for CGMS® *iPro*™ Continuous Glucose Recorder User Guide.
3. Chico A, Vidal-Rios P, Subira M, Novials A. *Diabetes Care*. 2003;26:1153-1157.

## Bone Changes Precede RA Symptoms

**B**one metabolism appears to change before patients show clinical signs of rheumatoid arthritis and could ultimately serve as an early marker of disease, based on a study of 79 patients.

"There appears to be an alteration in bone metabolism parallel to inflammation and autoimmunity in the asymptomatic preclinical phase of RA, which may reflect the beginning of joint destruction," according to Dr. Dirkjan van Schaardenburg, a rheumatologist at Jan van Breemen Institute in Amsterdam, and his coinvestigators.

They found significantly increased average levels of only P1NP (procollagen type I intact N-terminal propeptide) and osteoprotegerin in the group of preclinical RA patients, compared with a control group of healthy individuals. Specifically, P1NP increased by 5 ng/mL and osteoprotegerin increased by 4 pmol/L (*Ann. Rheum. Dis.* 2010 Oct. 18 [doi:10.1136/ard.2010.135723]).

Three blood samples taken 1, 2, and 5 years prior to the onset of symptoms were identified for 47 patients with RA; two samples were collected from 18 patients and one sample was collected from 14 patients. The individuals had been blood donors prior to developing the disease.

The study was funded by the Dutch Arthritis Association. The authors reported that they had no competing interests.

—Kerri Wachter